Cataract Clinical Trial
Verified date | April 2013 |
Source | Medical University of Vienna |
Contact | n/a |
Is FDA regulated | No |
Health authority | Austria: Ethikkommission |
Study type | Interventional |
Age-related cataract is the main cause of impaired vision in the elderly population
worldwide. In the UK, more than half of people who are over 65 have some cataract
development in one or both eyes. The only treatment that can restore functional visual
ability is cataract surgery where the opacified crystalline lens is removed by
phacoemulsification and an artificial intraocular lens is implanted. It is estimated that
around 10 million cataract operations are performed around the world each year. Cataract
operations are generally very successful, with a low risk of serious complications. The most
common risk is developing a condition called posterior capsule opacification (PCO), which
causes impaired vision to return.
During the past two decades, cataract surgery underwent tremendous change and modernisation
resulting in today's small incision phacoemulsification surgery and a safe technique with a
short rehabilitation time for the patient. The most frequent long-term complication of
cataract surgery remains to be posterior capsule opacification (PCO). In the past few years,
refinements in surgical technique and modifications in IOL design and material have led to a
decrease in the incidence of PCO.
It has been shown that a sharp posterior optic edge inhibits migration of lens epithelial
cells (LEC) behind the IOL optic and therefore have a lower incidence of posterior capsule
opacification (PCO). Most IOL designs have open-loop haptics that are connected to the optic
towards the end of the production process, also called multipiece designs.
For several reasons such as better ease of use with injector systems and higher efficiency
in the production process, companies have developed IOLs with open-loop haptics out of one
block of material, also called single-piece designs. In the case of such single-piece IOLs,
the haptics tend to be much thicker than with multipiece IOLs. A potential drawback of the
thick haptics maybe an incomplete closure of the capsule at the optic rim with a reduced
bending effect of the posterior capsule around the posterior optic edge. Additionally, the
posterior sharp edge is often discontinuous in the region of the haptic-optic junctions.
These locations may serve as a scaffold for LECs to migrate behind the IOL optic resulting
in PCO. Nowadays a multitude of different single piece IOLS are available, many of them
similar but of course with some differences in regard to the chemical composition of the
acrylic material and the IOL design.
The purpose of this study is to compare the intensity of posterior capsule opacification
(PCO) between two different 1-piece foldable hydrophobic acrylic intraocular lenses (IOLs)
over a period of 3 years.
Status | Completed |
Enrollment | 100 |
Est. completion date | September 2012 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - bilateral age-related cataract - good overall physical constitution Exclusion Criteria: - history of ocular disease or intraocular surgery - laser treatment - diabetes requiring medical control - glaucoma - severe retinal pathology that would make a postoperative visual acuity of 20/40 (decimal equivalent = 0.5) or better unlikely |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Posterior Capsule Opacification (PCO) | PCO = migration of lens epithelial cells behind the IOL optic after cataract surgery; scale 0-10 (0: no PCO; 10: maximum PCO) | 3 years | No |
Secondary | Percentage of Eyes With Neodymium:Yttrium-aluminium-garnet (Nd:YAG) Capsulotomy | Treatment of PCO in neodymium:yttrium-aluminium-garnet (Nd:YAG) capsulotomy. The frequency of this treatment will be asseseed in percentage values | 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |